Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics, a leader in psychiatric medicine, is advancing its mission with multiple Phase 2B clinical trials of MB22001, targeting Major Depressive Disorder and cancer-related depression and anxiety. The company, maintaining a steady pace with its scheduled dosing and patient recruitment, has fully funded these trials, with completion expected in 2025. Additionally, MindBio is set to commence another Phase 2B trial focusing on pre-menstrual syndromes.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.